Product Inquiry
Asset Licensing Opportunity
Resources
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| SHR-1918 | SHR-1918; SHR1918 | Phase 3 Clinical | Homozygous familial hypercholesterolemia; Hyperlipidemias | Details | |
| Zodasiran | ARO-ANG3; ARO-ANG33; VSA-003 (Arrowhead Pharmaceuticals) | Phase 3 Clinical | Roche Ltd | Hypertriglyceridemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Dyslipidemias; Hyperlipoproteinemia Type II | Details |
| LNA-043 | LNA-043 | Phase 2 Clinical | Novartis Pharma Ag | Knee Injuries; Osteoarthritis, Knee; Osteoarthritis | Details |
| Vupanorsen | ISIS-703802; PF-07285557 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Hypertriglyceridemia; Homozygous familial hypercholesterolemia; Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Hyperlipoproteinemia Type I; Hyperlipoproteinemias; Dyslipidemias; Cardiovascular Diseases; Hyperlipidemias; Hyperlipoproteinemia Type II | Details |
| LY-3561774 | LY-3561774; DCR-CM-1; DCR-CM1 | Phase 2 Clinical | Dicerna Pharmaceuticals Inc | Metabolic Diseases; Dyslipidemias; Hyperlipoproteinemias; Cardiovascular Diseases; Lipid Metabolism Disorders | Details |
| LY-3475766 | LY-3475766 | Phase 1 Clinical | Eli Lilly And Company | Dyslipidemias | Details |
| JS-401 | JS-401 | Phase 1 Clinical | Shanghai Junshi Biological Engineering Co Ltd | Hyperlipidemias | Details |
| NN-6491 | NN6491; NN-6491 | Phase 1 Clinical | Novo Nordisk A/S | Cardiovascular Diseases | Details |
| AZD-1705 | AZD1705; AZD-1705 | Phase 1 Clinical | Parexel, Astrazeneca Plc | Cardiovascular Diseases | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Evinacumab | REGN-1500 | Approved | Evkeeza | United States | Hypercholesterolemia; Homozygous familial hypercholesterolemia | Regeneron Pharmaceuticals Inc | 2021-02-11 | Homozygous familial hypercholesterolemia; Hypertriglyceridemia; Hypercholesterolemia; Metabolic Diseases | Details |
Customer Reviews